

11 1626



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

ATTORNEY DOCKET NO.:  
01662/50308

Application Number  
09/997,126

Filing Date  
November 29, 2001

Examiner  
Fiona Powers

Art Unit  
1626

Invention Title  
Novel Crystal Forms of Atorvastatin Hemi-Calcium  
and Processes for their Preparation as Well as Novel  
Processes for Preparing Other Forms

Inventor(s)  
ARONHIME et al.

Address to:  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 5/11/05  
Signature: *Kathy Fall*

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. § 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
3. A copy of a Supplemental European Search Report recently received in a corresponding EP application is also enclosed.
4. Applicants' attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
5. A duplicate copy of this communication is enclosed for charging purposes.

Dated:

MAY 10, 2005


By:

*Joseph A. Coppola*

Joseph A. Coppola (Reg. No. 38,413)

CUSTOMER NUMBER 26646

KENYON & KENYON  
One Broadway  
New York, New York 10004-1050  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)



**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT BY  
APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
1662/50308

SERIAL NO.  
09/997,126

APPLICANT  
ARONHIME et al.

FILING DATE  
November 29, 2001

GROUP  
1626

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/03958	February 6, 1997	PCT			x	
	WO 97/03959	February 6, 1997	PCT			x	
	WO 01/36384	May 25, 2001	PCT			x	
	WO 01/44180	June 21, 2001	PCT			x	
	WO 01/44181	June 21, 2001	PCT			x	
	WO 02/41834	May 30, 2002	PCT			x	
	WO 02/43732	June 6, 2002	PCT			x	
	WO 02/051804	July 4, 2002	PCT			x	
	WO 02/057229	July 25, 2002	PCT			x	
	WO 03/004470	January 16, 2003	PCT			x	
	WO 03/011826	February 13, 2003	PCT			x	
	WO 03/050085	June 19, 2003	PCT			x	
	WO 2004/022053	March 18, 2004	PCT			x	
	WO 2004/050618	June 17, 2004	PCT			x	

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	